Myeloperoxidase and free iron levels: Potential biomarkers for early detection and prognosis of ovarian cancer

Nicole M. Fletcher, Zhongliang Jiang, Rouba Ali-Fehmi, Nancy K. Levin, Jimmy Belotte, Michael A. Tainsky, Michael P. Diamond, Husam M. Abu-Soud, Ghassan M. Saed

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Objective: The study sought to identify whether a relationship exists between serum myeloperoxidase (MPO) and free iron with stages of ovarian cancer. Methods: Serum and tissue samples were collected from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA with post-hoc comparisons (p < 0.05 considered significant). Results: There was a significant increase in the level of free iron in serum and tissues obtained from stages II-IV as compared to early-stage (stage I) ovarian cancer. There was an overlap between early-stage and inflammation serum MPO levels, however serum free iron levels were significantly higher in early-stage. There was no significant change in serum free iron levels between non-cancer groups. In contrast, there was a significant increase in serum free iron levels in early-stage as compared to non-cancer groups. Conclusions: Collectively, these findings clearly indicate a role for the combination of serum MPO and free iron as biomarkers for early detection and prognosis of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalCancer Biomarkers
Volume10
Issue number6
DOIs
StatePublished - 2011
Externally publishedYes

Keywords

  • Myeloperoxidase
  • biomarkers
  • free iron
  • ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Myeloperoxidase and free iron levels: Potential biomarkers for early detection and prognosis of ovarian cancer'. Together they form a unique fingerprint.

Cite this